SLC5A2 and heart failure: In patients with stage 3/4 CKD combined with heart failure (HFrEF), SGLT2 inhibitors reduced the risk of the primary cardiovascular outcome by 21% (Fig 4, HR 0.79, [95% CI 0.70–0.89], I2 = 0.00%).